MA37400B1 - Composés hétérocyclyle en tant qu'inhibiteurs de mek - Google Patents

Composés hétérocyclyle en tant qu'inhibiteurs de mek

Info

Publication number
MA37400B1
MA37400B1 MA37400A MA37400A MA37400B1 MA 37400 B1 MA37400 B1 MA 37400B1 MA 37400 A MA37400 A MA 37400A MA 37400 A MA37400 A MA 37400A MA 37400 B1 MA37400 B1 MA 37400B1
Authority
MA
Morocco
Prior art keywords
compounds
mek inhibitors
present
heterocyclyl compounds
formula
Prior art date
Application number
MA37400A
Other languages
English (en)
Other versions
MA37400A1 (fr
Inventor
Bhavesh Dave
Rakesh Banerjee
Samiron Phukan
Abhijit Khoje
Rajkumar Hangarge
Jitendra Jadhav
Venkata Palle
Rajender Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37400(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA37400A1 publication Critical patent/MA37400A1/fr
Publication of MA37400B1 publication Critical patent/MA37400B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La présente invention concerne des composés hétéroaryle en tant qu'inhibiteurs de mek. Ces composés comprennent des composés hétéroaryle de formule (i), leurs sels pharmaceutiquement acceptables, des combinaisons avec un médicament approprié et des compositions pharmaceutiques de ceux-ci. La présente invention concerne également des procédés de préparation des composés et leur utilisation dans des méthodes de traitement. Les composés selon la présente invention sont représentés par la formule (i).
MA37400A 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek MA37400B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051908 WO2013136249A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek

Publications (2)

Publication Number Publication Date
MA37400A1 MA37400A1 (fr) 2016-05-31
MA37400B1 true MA37400B1 (fr) 2019-11-29

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
MA37400A MA37400B1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37405A MA37405A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA37405A MA37405A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle

Country Status (36)

Country Link
US (5) US9428499B2 (fr)
EP (2) EP2834237B1 (fr)
JP (3) JP6431770B2 (fr)
KR (4) KR20140138910A (fr)
CN (4) CN104271577A (fr)
AP (2) AP3859A (fr)
AU (4) AU2013234014B2 (fr)
BR (1) BR112014022713B1 (fr)
CA (2) CA2865167C (fr)
CL (2) CL2014002412A1 (fr)
CO (2) CO7170131A2 (fr)
CR (2) CR20140464A (fr)
CU (2) CU24272B1 (fr)
DK (2) DK2834236T3 (fr)
DO (2) DOP2014000204A (fr)
EA (2) EA028232B1 (fr)
ES (2) ES2741896T3 (fr)
GE (2) GEP201706671B (fr)
GT (2) GT201400196A (fr)
HK (2) HK1202538A1 (fr)
IL (2) IL234559A (fr)
IN (2) IN2014MN01755A (fr)
MA (2) MA37400B1 (fr)
MX (3) MX355526B (fr)
MY (2) MY174188A (fr)
NI (2) NI201400108A (fr)
NZ (2) NZ629432A (fr)
PE (2) PE20141973A1 (fr)
PH (2) PH12014502041B1 (fr)
PL (1) PL2834237T3 (fr)
SG (2) SG11201405006PA (fr)
TN (2) TN2014000356A1 (fr)
TR (1) TR201811976T4 (fr)
UA (2) UA114907C2 (fr)
WO (2) WO2013136254A1 (fr)
ZA (1) ZA201406186B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
KR20140138910A (ko) 2012-03-14 2014-12-04 루핀 리미티드 헤테로사이클릴 화합물
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
CN104936945B (zh) * 2013-10-25 2017-11-03 上海恒瑞医药有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用
WO2016009306A1 (fr) * 2014-07-15 2016-01-21 Lupin Limited Composés hétérocyclyles utilisés comme inhibiteurs de mek
WO2016035008A1 (fr) * 2014-09-04 2016-03-10 Lupin Limited Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (fr) 2015-02-20 2021-08-04 Incyte Corporation Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
LT3728254T (lt) 2017-12-21 2023-05-10 Boehringer Ingelheim International Gmbh Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CA3099116A1 (fr) 2018-05-04 2019-11-07 Incyte Corporation Sels d'un inhibiteur de fgfr
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114375202A (zh) 2019-06-19 2022-04-19 勃林格殷格翰国际有限公司 抗癌组合疗法
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021018866A1 (fr) * 2019-07-30 2021-02-04 Edvince Ab Inhibiteur de mek pour le traitement d'un accident vasculaire cérébral
EP3797899A1 (fr) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Dispositif et procédé de détection d'un mouvement d'un corps dans une installation industrielle
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
CA3162010A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Derives d'un inhibiteur de fgfr
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN116034106A (zh) 2020-06-02 2023-04-28 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117479942A (zh) 2021-04-09 2024-01-30 勃林格殷格翰国际有限公司 抗癌疗法
AU2022258968A1 (en) * 2021-04-16 2023-10-19 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023099620A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Composés de dégradation de kras comprenant des 2-amino-3-cyano thiophènes annelés
WO2023099592A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
WO2023099608A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
WO2003062236A1 (fr) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
BRPI0511967B8 (pt) * 2004-06-11 2021-05-25 Japan Tobacco Inc derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
EA201101533A1 (ru) 2009-04-21 2012-05-30 Новартис Аг Гетероциклические соединения в качестве ингибиторов mek
KR20140138910A (ko) 2012-03-14 2014-12-04 루핀 리미티드 헤테로사이클릴 화합물

Also Published As

Publication number Publication date
US9827247B2 (en) 2017-11-28
CL2014002411A1 (es) 2015-04-06
WO2013136249A1 (fr) 2013-09-19
PH12014502040A1 (en) 2014-11-24
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
CR20140464A (es) 2014-11-28
GEP201706774B (en) 2017-11-27
AU2018202568B2 (en) 2019-05-09
DOP2014000203A (es) 2015-02-15
SG11201405007QA (en) 2014-10-30
EP2834236B1 (fr) 2019-05-22
KR20140138911A (ko) 2014-12-04
MX2014010925A (es) 2015-04-10
US20160331753A1 (en) 2016-11-17
KR20190073597A (ko) 2019-06-26
MY174188A (en) 2020-03-12
CN104271577A (zh) 2015-01-07
UA114906C2 (uk) 2017-08-28
US9555035B2 (en) 2017-01-31
BR112014022713B1 (pt) 2021-09-08
PH12014502041A1 (en) 2014-11-24
US9969731B2 (en) 2018-05-15
KR102240101B1 (ko) 2021-04-14
ZA201406186B (en) 2016-06-29
ES2684517T3 (es) 2018-10-03
AU2013234009B2 (en) 2016-10-27
DK2834236T3 (da) 2019-08-26
US9573944B2 (en) 2017-02-21
US9428499B2 (en) 2016-08-30
CA2865164C (fr) 2021-06-08
MX366426B (es) 2019-07-08
CU20140109A7 (es) 2014-11-27
DK2834237T3 (en) 2018-08-27
PE20141974A1 (es) 2014-12-12
SG11201405006PA (en) 2014-10-30
US20170101408A1 (en) 2017-04-13
IN2014MN01754A (fr) 2015-07-03
US20150133424A1 (en) 2015-05-14
IN2014MN01755A (fr) 2015-07-03
AU2017200493B2 (en) 2018-03-29
AU2013234014A1 (en) 2014-09-25
IL234560A (en) 2017-06-29
NZ629432A (en) 2017-01-27
CO7170131A2 (es) 2015-01-28
HK1206020A1 (en) 2015-12-31
MX355474B (es) 2018-04-16
CL2014002412A1 (es) 2015-03-06
AP3859A (en) 2016-10-31
JP2015509975A (ja) 2015-04-02
ES2741896T3 (es) 2020-02-12
NI201400108A (es) 2014-11-28
JP6093384B2 (ja) 2017-03-08
CA2865164A1 (fr) 2013-09-19
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
PH12014502041B1 (en) 2014-11-24
CN104203947A (zh) 2014-12-10
NI201400107A (es) 2014-11-26
GT201400195A (es) 2017-11-09
EP2834236A1 (fr) 2015-02-11
EP2834237A1 (fr) 2015-02-11
AP2014008008A0 (en) 2014-10-31
US20170112840A1 (en) 2017-04-27
UA114907C2 (uk) 2017-08-28
CU24272B1 (es) 2017-08-08
EA201491671A1 (ru) 2014-12-30
AP2014008009A0 (en) 2014-10-31
AU2013234014B2 (en) 2017-02-02
CU20140110A7 (es) 2014-11-27
GT201400196A (es) 2017-09-28
CU24335B1 (es) 2018-04-03
MA37405A1 (fr) 2016-03-31
BR112014022713A2 (fr) 2017-06-20
MA37400A1 (fr) 2016-05-31
CA2865167C (fr) 2019-08-06
CN107698585A (zh) 2018-02-16
TN2014000357A1 (en) 2015-12-21
JP2015514056A (ja) 2015-05-18
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
CN108383836B (zh) 2021-11-12
MX355526B (es) 2018-04-20
KR20190100472A (ko) 2019-08-28
PH12014502040B1 (en) 2014-11-24
KR102241111B1 (ko) 2021-04-15
KR20140138910A (ko) 2014-12-04
US20150299186A1 (en) 2015-10-22
CA2865167A1 (fr) 2013-09-19
CN108383836A (zh) 2018-08-10
IL234559A (en) 2017-06-29
MX2014010928A (es) 2015-04-10
JP6431770B2 (ja) 2018-11-28
AU2017200493A1 (en) 2017-02-16
GEP201706671B (en) 2017-05-25
AP3834A (en) 2016-09-30
EA028232B1 (ru) 2017-10-31
DOP2014000204A (es) 2015-02-15
AU2018202568A1 (en) 2018-05-10
EA029768B1 (ru) 2018-05-31
WO2013136254A1 (fr) 2013-09-19
PE20141973A1 (es) 2014-12-12
JP6630771B2 (ja) 2020-01-15
TR201811976T4 (tr) 2018-09-21
JP2018115215A (ja) 2018-07-26
EP2834237B1 (fr) 2018-06-06
AU2013234009A1 (en) 2014-09-25
NZ629442A (en) 2016-12-23
PL2834237T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
MD4736C1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
NZ703064A (en) Inhibitors of hepatitis c virus
MA40225A (fr) Composés dihydroisoquinolinone substitués
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
EA201591195A1 (ru) Новые хинолоновые производные
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
TR201902057T4 (tr) Tetrasiklin bileşikleri.